Compare LADR & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LADR | WVE |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2013 | 2015 |
| Metric | LADR | WVE |
|---|---|---|
| Price | $9.71 | $5.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $12.25 | ★ $29.81 |
| AVG Volume (30 Days) | 1.1M | ★ 2.3M |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 8.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $31.66 | N/A |
| Revenue Next Year | $16.92 | $85.67 |
| P/E Ratio | $70.07 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $9.43 | $5.02 |
| 52 Week High | $11.92 | $21.73 |
| Indicator | LADR | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 45.39 |
| Support Level | N/A | $5.49 |
| Resistance Level | $10.42 | $6.48 |
| Average True Range (ATR) | 0.23 | 0.26 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 42.70 | 36.47 |
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.